Synapse Open Synapse
Biology

Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

BioPharma Dive · · 3 min read

The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.

Latest from BioPharma Dive